latest news releases from the newsroom
Endovasc Ltd., Inc.
Endovasc Creates Orphan Drug Trust; Financial Instrument Provides 50 Percent Tax Credit for Investors and Fast-Tracks Endovasc Through Phase III Human Clinical Trials
MONTGOMERY, Texas, Sept. 24, 2002 (PRIMEZONE) -- Endovasc Ltd., Inc. (OTCBB:ENVC), a biotechnology company with two cardiovascular drugs approved for final FDA Phase III trials, announced today that it has established an Orphan Drug Trust to develop drugs for rare diseases under the Orphan Drug Act, as utilized by Celgene (Nasdaq:CELG) for Thalidomide, a treatment of severe recurrent aphthous stomatitis in severely immunocompromised patients, and Abgenix (Nasdaq:ABGX) for Gavilimomab, an acute graft-versus-host disease (aGVHD).
Viscount Systems Inc.
Viscount Receives Grants of $235,000
BURNABY, British Columbia., Sept. 24, 2002 (PRIMEZONE) -- Viscount Systems Inc. (OTCBB:VSYS) President and CEO Stephen Pineau is pleased to announce that the Company has received $235,000 in scientific tax funding grants from the Government of Canada for the 2000 tax year. The $235,000 relates to the Scientific Research and Experimental Development (SR&ED) program that encourages investment in technologies which display an element of scientific uncertainty and technological advancement. Viscount's claim focused on its new MESH (Multimedia Embedded Security Hub) system and the company only submitted elements which met the strict Government of Canada criteria for acceptance.
Pacific Fuel Cell Corp.
Pacific Fuel Cell Corp. Announces Its Listing on the Berlin Stock Exchange
TUSTIN, Calif., Sept. 24, 2002 (PRIMEZONE) -- Pacific Fuel Cell Corp. (OTCBB:PFCE) is pleased to announce that the Company has filed its application for a market listing in Germany to introduce PFCE to the European investment community. PFCE has met admission requirements and has been accepted for listing on the Berlin Stock Exchange. By listing on the Berlin exchange we offer European investors the opportunity to trade the company's highly liquid shares. European investors are trading American shares much more often, and in continually larger amounts.
Teleca's Shareholding in Pronyx Amounts to 94.7 per cent
MALMO, Sweden, Sept. 24, 2002 (PRIMEZONE) -- Teleca AB's ("Teleca") (Stockholm:TELCb) public offer to the holders of shares and convertible debentures issued by Pronyx AB (publ) ("Pronyx") (Stockholm:PRYX) has, following the end of the extended acceptance period on September 20, 2002, finally been accepted to such extent that Teleca has become owner of 94.7 per cent of the shares in Pronyx. After full conversion of the convertible debentures issued, Teleca's holding amounts to 95.0 per cent of the shares in Pronyx.
Atlas Copco Electric Tools to Strengthen Its Competitiveness
STOCKHOLM, Sweden, Sept. 24, 2002 (PRIMEZONE) -- Atlas Copco have launched the exclusive Milwaukee brand of electric professional tools across Europe, and are taking new marketing initiatives to grow the AEG Power Tools business. By establishing a manufacturing subsidiary in the Czech Republic, an accelerated expansion in Eastern Europe is enabled, and production efficiency will increase.
Integra LifeSciences Holdings Corp.
Integra NeuroSciences Announces Launch of Camino Single Parameter Monitor in Europe and Other International Markets
PLAINSBORO, N.J., Sept. 24, 2002 (PRIMEZONE) -- Integra LifeSciences Holdings Corporation (Nasdaq:IART) today announced that Integra NeuroSciences has launched the Camino(R) Single Parameter Monitor ("SPM-1") for the measurement of intracranial pressure into Europe and certain other international markets. The SPM-1 product provides Integra's international customers with a low cost alternative to the Camino Multi Parameter Monitor, which measures intracranial pressure and temperature and displays calculated cerebral perfusion pressure. The SPM-1 is used in conjunction with Integra's existing line of fiber optic-based Camino catheters.
Women First HealthCare, Inc.
Women First HealthCare Announces the Availability of Esclim, Ortho-est Tablets and Midrin to all Medco Plan Sponsors (formerly Merck-Medco)
SAN DIEGO, Sept. 24, 2002 (PRIMEZONE) -- Women First HealthCare, Inc. (Nasdaq:WFHC), a specialty pharmaceutical company, today announced that its Esclim(tm) (estradiol transdermal system), Ortho-est(r) Tablets (estropipate, USP), and Midrin(r) (isometheptene mucate, USP, dichloralphenazone, USP and acetaminophen, USP) are available to all Medco Plan Sponsors with no intervention from Medco. Medco Health Solutions Inc., formerly Merck-Medco, is one of the country's largest pharmacy benefit managers (PBMs). Beginning October 1, 2002, all five doses of Esclim will be available to Medco Plan Sponsors, as will Ortho-est Tablets and Midrin.
TietoEnator Provides Finland's Most Extensive Library System for the Tampere Region
ESPOO, Finland, Sept. 24, 2002 (PRIMEZONE) -- The 13 city libraries of the Tampere region and the Tampere City/Regional Library have signed an agreement concerning the most extensive common library system in Finland. The solution is based on TietoEnator's PallasPro library system. The new system will be implemented gradually, and the first libraries will join the common system during the fall of 2002.